Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, ...

October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

We are now well into what is often called the “psychedelic renaissance,” and the field has made genuine progress alongside all the early excitement. Many groups new to the realities of FDA oversight ...

The Business of Biotech was taped in front of a live audience in Boston during the BIO conference last month, and we couldn’t have asked for a better guest to test out this new format. Amber Salzman, ...

Smart money will find good ideas, and if you follow the money in biotech these days, that means looking to China. From January to mid-May 2025, Chinese biotechnology companies had announced licensing ...

The biopharma industry is rapidly evolving. As such, biopharma companies are facing a variety of operational challenges stemming from a high volume of siloed data coupled with regulatory scrutiny that ...

Patient safety is the top priority for regulators. While the industry and the public advocate for alternatives to animal testing, regulators require strong evidence that alternatives are equally safe ...

In this series, we will monitor emerging policies and priorities from the new Trump administration and its agencies that are expected to have particular effects on healthcare and life science-related ...

What does strategy look like for a drug development program? The word strategy can mean different things to different individuals. If you polled a group on a development team, you may receive ...

Vivani’s subdermal implant NanoPortal device, a platform drug delivery technology, is designed to deliver a near-constant and minimally fluctuating dose of an active pharmaceutical drug for a duration ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...